+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Meningococcal Vaccines Market Size, Share & Trends Analysis Report by Brand (Menactra, Menveo, Bexsero, Trumenba, Nimenrix), by Type, by Serotype, by Age Group, by Sales Channel, by Region and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 163 Pages
  • April 2022
  • Region: Global
  • Grand View Research
  • ID: 5595856
The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%. Increasing prevalence of meningitis is one of the major factors attributed to the market growth. For instance, according to ECDC, it was estimated that in 2017, 3,221 confirmed cases were observed in EU member states, wherein 58% cases were found in the U.K., France, Spain, and Germany. Moreover, a high incidence of meningitis disease is found in the “meningitis belt” of sub-Saharan Africa, and approximately 30,000 cases are reported every year in this region.



In addition, rising FDA approval for meningococcal vaccines is expected to boost the growth. For instance, in April 2020, Sanofi received FDA approval for its MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive meningococcal disorders in individuals at least two years old. The increase in approval of novel vaccines is expected to improve meningococcal prevention which in turn, is anticipated to drive the market.

Initiatives undertaken by the government to combat the rising incidence of the disease are anticipated to boost the meningococcal vaccine market growth. For instance, from April 2019, Nimenrix was made available for free as a part of the National Immunization Program (NIP) in Australia for the age group 15 to 19 years. Nimenrix is a quadrivalent meningococcal vaccine that targets serogroups A, C, W & Y.

According to WHO, as of 2021, 24 of the 26 nations in the meningitis belt have introduced mass preventive campaigns targeting the age of 1 to 29 years. Moreover, around 13 nations have undertaken the vaccine in their national routine immunization programs. Such initiatives undertaken by countries having high disease burdens are expected to boost the market growth.

Non-profit organizations entering into strategic initiatives such as partnering, alliances, and others to improve access to new vaccines for vulnerable children are anticipated to drive the market. For instance, in September 2021, WHO and its partners announced the first-ever global strategy to defeat meningitis. This initiative aims to reduce epidemics of bacterial meningitis. Under this strategy, WHO goals to save more than 200,000 lives annually.

The availability of vaccines at lower prices in countries with an increasing prevalence of the meningococcal disease is anticipated to fuel the revenue of the manufacturers and drive the meningococcal vaccine market. For instance, under Meningitis Vaccine Project, MenAfriVac costs less than USD 0.5 per dose.

Meningococcal Vaccines Market Report Highlights

  • Quadrivalent vaccines dominated the type segment owing to their ability to target four serogroups and the strong presence of vaccines such as Menveo, Menactra, and Nimenrix.
  • The infants (0-2 years) segment accounted for the significant revenue share, by age group, in 2021. The increasing prevalence of meningitis in the age group 9 months to 11 years contributed to the segment growth.
  • Asia Pacific region is expected to witness the highest CAGR over the forecast period. High unmet needs, rising healthcare expenditure, and a large population base in this region are likely to bolster the market.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Meningococcal Vaccines Market

What is the estimated value of the Global Meningococcal Vaccines Market?

The Global Meningococcal Vaccines Market was estimated to be valued at $3.05 Billion in 2022.

What is the growth rate of the Global Meningococcal Vaccines Market?

The growth rate of the Global Meningococcal Vaccines Market is 6.2%, with an estimated value of $4.92 Billion by 2030.

What is the forecasted size of the Global Meningococcal Vaccines Market?

The Global Meningococcal Vaccines Market is estimated to be worth $4.92 Billion by 2030.

Who are the key companies in the Global Meningococcal Vaccines Market?

Key companies in the Global Meningococcal Vaccines Market include Sanofi, Merck & Co. Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Pfizer, Inc. and Petrovax.

Table of Contents

Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List Of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
1.8.3 Objective 3
1.8.4 Objective 4
1.9 List Of Abbreviations
Chapter 2. Executive Summary
2.1 Market Summary
Chapter 3. Meningococcal Vaccines Market Variables, Trends, and Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Product Pipeline Analysis
3.3 Regulatory Framework
3.3.1 North America
3.3.2 Europe
3.3.3 Asia Pacific
3.3.4 Latin America
3.3.5 Middle East & Africa
3.4 Market Driver Analysis
3.4.1 Rising Incidence Of Meningitis
3.4.2 Rising R&D In Meningococcal Vaccines
3.4.3 Increasing Immunization Programs and Government Initiatives
3.4.4 Growing Support by Healthcare Services In Providing Low-Cost Meningococcal Vaccine
3.5 Market Restraint Analysis
3.5.1 High-Cost Associated With Storage and Supply Of Vaccines
3.5.2 Challenges Associated With Vaccine Development
3.6 Swot Analysis, by Factor (Political & Legal, Economic, and Technological)
3.7 Porter’s Five Forces Analysis
3.8 Major Deals and Strategic Alliances Analysis
3.8.1 New Product Launches
3.8.2 Mergers and Acquisitions
3.8.3 Expansion
3.8.4 Partnerships
3.8.5 Marketing and Promotions
3.8.6 Market Entry Strategies
Chapter 4. Meningococcal Vaccines Market: Segment Analysis, by Type 2017-2030 (USD Million)
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Meningococcal Vaccines Market, by Type, 2017 To 2030
4.5 Market Size & Forecasts and Trend Analyses, 2017 To 2030
4.5.1 Bivalent
4.5.1.1 Bivalent Market Estimates and Forecast 2017-2030 (USD Million)
4.5.2 Quadrivalent
4.5.2.1 Quadrivalent Market Estimates and Forecast 2017-2030 (USD Million)
4.5.3 Others
4.5.3.1 Others Market Estimates and Forecast 2017-2030 (USD Million)
Chapter 5. Meningococcal Vaccines Market: Segment Analysis, by Brand 2017-2030 (USD Million)
5.1 Definition and Scope
5.2 Brand Market Share Analysis, 2020 & 2030
5.3 Segment Dashboard
5.4 Global Meningococcal Vaccines Market, by Brand, 2017 To 2030
5.5 Market Size & Forecasts and Trend Analyses, 2017 To 2030
5.5.1 Menactra
5.5.1.1 Menactra Market Estimates and Forecast 2017-2030 (USD Million)
5.5.2 Menveo
5.5.2.1 Menveo Market Estimates and Forecast 2017-2030 (USD Million)
5.5.3 Nimenrix
5.5.3.1 Nimenrix Market Estimates and Forecast 2017-2030 (USD Million)
5.5.4 Trumenba
5.5.4.1 Trumenba Market Estimates and Forecast 2017-2030 (USD Million)
5.5.5 BEXSERO
5.5.5.1 Bexsero Market Estimates and Forecast 2017-2030 (USD Million)
5.5.6 OTHERS
5.5.6.1 Others Market Estimates and Forecast 2017-2030 (USD Million)
Chapter 6. Meningococcal Vaccines Market: Segment Analysis, by Age Group 2017-2030 (USD Million)
6.1 Definition and Scope
6.2 Age Group Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Meningococcal Vaccines Market, by Age Group, 2017 To 2030
6.5 Market Size & Forecasts and Trend Analyses, 2017 To 2030
6.5.1 INFANTS (0-2 YEARS)
6.5.1.1 Infants Market Estimates and Forecast 2017-2030 (USD Million)
6.5.2 CHILDREN and ADULTS (2 YEARS and ABOVE)
6.5.2.1 Children and Adults Market Estimates and Forecast 2017-2030 (USD Million)
Chapter 7. Meningococcal Vaccines Market: Segment Analysis, by Serotype 2017-2030 (USD Million)
7.1 Definition and Scope
7.2 Serotype Market Share Analysis, 2021 & 2030
7.3 Segment Dashboard
7.4 Global Meningococcal Vaccines Market, by Serotype, 2017 To 2030
7.5 Market Size & Forecasts and Trend Analyses, 2017 To 2030
7.5.1 SEROTYPE A
7.5.1.1 Serotype A Market Estimates and Forecast 2017-2030 (USD Million)
7.5.2 SEROTYPE B
7.5.2.1 Serotype B Market Estimates and Forecast 2017-2030 (USD Million)
7.5.3 SEROTYPE C
7.5.3.1 Serotype C Market Estimates and Forecast 2017-2030 (USD Million)
7.5.4 SEROTYPE W-135
7.5.4.1 Serotype W Market Estimates and Forecast 2017-2030 (USD Million)
7.5.5 SEROTYPE Y
7.5.5.1 Serotype Y Market Estimates and Forecast 2017-2030 (USD Million)
Chapter 8. Meningococcal Vaccines Market: Segment Analysis, by Sales Channel 2017-2030 (USD Million)
8.1 Definition and Scope
8.2 Sales Channel Market Share Analysis, 2021 & 2030
8.3 Segment Dashboard
8.4 Global Meningococcal Vaccines Market, by Sales Channel, 2017 To 2030
8.5 Market Size & Forecasts and Trend Analyses, 2017 To 2030
8.5.1 PRIVATE
8.5.1.1 Private Market Estimates and Forecast 2017-2030 (USD Million)
8.5.2 PUBLIC
8.5.2.1 Public Market Estimates and Forecast 2017-2030 (USD Million)
Chapter 9. Meningococcal Vaccines Market: Segment Analysis, by Region 2017-2030 (USD Million)
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2021 & 2030
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 Market Size & Forecasts and Trend Analyses, 2017 To 2030
9.5.1 NORTH AMERICA
9.5.1.1 North America Market Estimates and Forecasts 2017-2030 (USD Million)
9.5.1.2 U.S.
9.5.1.2.1 U.S. Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.1.3 Canada
9.5.1.3.1 Canada Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2 EUROPE
9.5.2.1 Europe Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.2 Germany
9.5.2.2.1 Germany Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.3 U.K.
9.5.2.3.1 U.K. Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.4 France
9.5.2.4.1 France Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.5 Spain
9.5.2.5.1 Spain Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.6 Italy
9.5.2.6.1 Italy Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.7 Russia
9.5.2.7.1 Russia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.8 Belarus
9.5.2.8.1 Belarus Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.9 Georgia
9.5.2.9.1 Georgia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.2.10 Moldova
9.5.2.10.1 Moldova Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3 ASIA PACIFIC
9.5.3.1 Asia Pacific Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.2 Japan
9.5.3.2.1 Japan Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.3 China
9.5.3.3.1 China Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.4 India
9.5.3.4.1 India Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.5 South Korea
9.5.3.5.1 South Korea Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.6 Australia
9.5.3.6.1 Australia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.7 Singapore
9.5.3.7.1 Singapore Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.8 Thailand
9.5.3.8.1 Thailand Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.9 Vietnam
9.5.3.9.1 Vietnam Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.10 Malaysia
9.5.3.10.1 Malaysia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.11 Indonesia
9.5.3.11.1Indonesia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.12 Kazakhstan
9.5.3.12.1Kazakhstan Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.13 Kyrgyzstan
9.5.3.13.1Kyrgyzstan Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.14 Armenia
9.5.3.14.1Armenia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.15 Azerbaijan
9.5.3.15.1Azerbaijan Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.16 Tajikistan
9.5.3.16.Tajikistan Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.17 Turkmenistan
9.5.3.17.1 Turkmenistan Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.3.18 Uzbekistan
9.5.3.18.1Uzbekistan Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4 LATIN AMERICA
9.5.4.1 Latin America Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.2 Brazil
9.5.4.2.1 Brazil Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.3 Mexico
9.5.4.3.1 Mexico Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.4 Argentina
9.5.4.4.1 Argentina Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.5 Chile
9.5.4.5.1 Chile Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.6 Cuba
9.5.4.6.1 Cuba Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.7 Ecuador
9.5.4.7.1 Ecuador Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.8 Peru
9.5.4.8.1 Peru Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.9 Colombia
9.5.4.9.1 Colombia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.4.10 Venezuela
9.5.4.10.1 Venezuela Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5 MIDDLE EAST & AFRICA
9.5.5.1 Middle-East and Africa Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.2 South Africa
9.5.5.2.1 South Africa Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.3 Saudi Arabia
9.5.5.3.1 Saudi Arabia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.4 UAE
9.5.5.4.1 UAE Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.5 Algeria
9.5.5.5.1 Algeria Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.6 Egypt
9.5.5.6.1 Egypt Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.7 Tunisia
9.5.5.7.1 Tunisia Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.8 Iran
9.5.5.8.1 Iran Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.9 Turkey
9.5.5.9.1 Turkey Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.10 Iraq
9.5.5.10.1Iraq Market Estimate and Forecasts 2017-2030 (USD Million)
9.5.5.11 Morocco
9.5.5.11.1Morocco Market Estimate and Forecasts 2017-2030 (USD Million)
Chapter 10. Competitive Landscape
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 ANSOFF MATRIX
10.1.2 COMPANY/COMPETITION CATEGORIZATION (KEY INNOVATORS, MARKET LEADERS, EXPANSION)
10.1.3 INNOVATORS
10.2 Vendor Landscape
10.2.1 LIST OF KEY DISTRIBUTORS and CHANNEL PARTNERS
10.2.2 KEY COMPANY MARKET SHARE ANALYSIS, 2021
10.3 Public Companies
10.3.1 COMPANY MARKET POSITION ANALYSIS
10.3.2 COMPETITIVE DASHBOARD ANALYSIS
10.4 Private Companies
10.4.1 KEY EMERGING COMPANIES/TECHNOLOGY DISRUPTORS/INNOVATORS
10.4.2 REGIONAL NETWORK MAP
10.5 Strategy Framework
10.6 Company Profile
10.6.1 SANOFI
10.6.1.1 Company Overview
10.6.1.2 Financial Performance
10.6.1.3 Product Benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 MERCK & CO., INC.
10.6.2.1 Company Overview
10.6.2.2 Financial Performance
10.6.2.3 Product Benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 GLAXOSMITHKLINE PLC
10.6.3.1 Company Overview
10.6.3.2 Financial Performance
10.6.3.3 Product Benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 SERUM INSTITUTE OF INDIA PVT. LTD.
10.6.4.1 Company Overview
10.6.4.2 Product Benchmarking
10.6.4.3 Strategic Initiatives
10.6.5 PFIZER, INC.
10.6.5.1 Company Overview
10.6.5.2 Financial Performance
10.6.5.3 Product Benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 WALWAX BIOTECHNOLOGY CO., LTD
10.6.6.1 Company Overview
10.6.6.2 Product Benchmarking
10.6.6.3 Strategic Initiatives
10.6.7 PETROVAX
10.6.7.1 Company Overview
10.6.7.2 Product Benchmarking
10.6.7.3 Strategic Initiatives

Companies Mentioned

  • Sanofi
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Pfizer, Inc.
  • Walwax Biotechnology Co. Ltd
  • Petrovax

Methodology

Loading
LOADING...